Search

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is responsible for the ongoing COVID-19 pandemic, and causes many health complications, including major lung diseases. Besides investigations into the virology of SARS-CoV-2, understanding the immunological routes underlying the clinical manifestations of COVID-19 is important for developing effective therapeutic interventions. The clearance of SARS-CoV-2-infected apoptotic cells by professional efferocytes, through a process termed as 'efferocytosis', is essential for maintaining tissue homeostasis, and reducing the chances of health complications caused by SARS-CoV-2 infection. In this review, we focus on the cellular events leading to engagement of the SARS-CoV-2 with type 2 alveolar cells, and how SARS-COV-2 infection impairs the macrophage anti-inflammatory programming. We also discuss accounts of impaired efferocytosis, and the "cytokine storm" which occur concomitantly with the SARS-CoV-2 infection. Finally, we propose how targeting impaired efferocytosis, due to the SARS-CoV-2 infection, may be a beneficial therapeutic strategy to combat COVID-19, and its complications. [Display omitted] • Efferocytosis, a physiological process essential for maintaining tissue homeostasis, is hampered by SARS-CoV-2 infection. • Engagement with SARS-CoV-2 impairs the efficiency of macrophages, which mediate the phagocytic process. • An imbalance in immune signalling also triggers a 'cytokine storm', which causes tissue inflammation and damage. • Major lung diseases and autoimmune disorders have emerged as common complications in COVID-19 patients. • Boosting efferocytosis, post SARS-CoV-2 infection, could be an effective strategy against COVID-19 and its complications. [ABSTRACT FROM AUTHOR]